Funding for this research was provided by:
Open Access funding enabled and organized by Projekt DEAL.
Article History
Accepted: 19 August 2024
First Online: 30 September 2024
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. There was no specific funding for conducting this study.
: M.L. received research grants and/or speaker honoraria from Amicus Therapeutics, Sanofi, Chiesi, Sumitomo Pharma, and Takeda. E.B. received research grants and/or speaker honoraria from Amicus Therapeutics, Sanofi, Chiesi, Takeda, and Eleva. E.R.M. has nothing to declare.
: The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.
: All investigations were performed after approval by the Medical Association of Westphalian-Lippe and the Ethics Committee of the Medical Faculty of the University of Muenster (project no. 2011-347-f, date of report 7 July 2011) and in accordance with the Declaration of Helsinki.
: Written informed consent was obtained from all included patients for analysis and publication.
: Not applicable.
: All authors contributed to the article by participating in the conception and design (M.L.), acquisition of data (M.L., E.R.M., and E.B.) or formal analysis (M.L. and E.R.M.) and interpretation of data (M.L., E.R.M., and E.B.), drafting the article (M.L. and E.R.M.) or revising it critically for important intellectual content (E.B.). All authors read and approved the final version of the manuscript.